Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kymera Therapeutics Inc (NQ: KYMR ) 33.29 -1.58 (-4.53%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 408,446 Open 34.46 Bid (Size) 13.41 (1) Ask (Size) 40.00 (1) Prev. Close 34.87 Today's Range 33.19 - 34.87 52wk Range 9.600 - 45.31 Shares Outstanding 55,307,775 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting Today 7:00 EDT From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting June 01, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Performance YTD +31.32% +31.32% 1 Month -5.13% -5.13% 3 Month -15.74% -15.74% 6 Month +30.81% +30.81% 1 Year +29.03% +29.03% More News Read More Kymera Therapeutics to Participate in Upcoming June Investor Conferences May 29, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews May 24, 2024 Via Benzinga Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) April 22, 2024 Via Benzinga Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views February 23, 2024 Via Benzinga Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting May 23, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting May 22, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting May 14, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming May Investor Conferences May 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update May 02, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 April 25, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting April 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting March 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming March Investor Conferences February 28, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know February 27, 2024 Via Benzinga Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update February 22, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 February 15, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference January 31, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For February 22, 2024 February 22, 2024 Via Benzinga Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs January 09, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares January 09, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering January 05, 2024 Via Investor's Business Daily Kymera Therapeutics Announces Pricing of $275 Million Public Offering January 05, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
